CP-724,714 in Treating Patients With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: CP-724,714 may stop the growth of tumor cells by blocking the enzymes necessary
for tumor cell growth.
PURPOSE: Phase I trial to study the effectiveness of CP-724,714 in treating patients who have
metastatic HER2-overexpressing breast cancer.